【Asset for Licensing】Novel CDH6-targeted ADC conjugated with TOPO1 inhibitor payload

Asset: Novel CDH6-targeted ADC conjugated with TOPO1 inhibitor payload
Development Stage: Clinical stage
Indication: Ovarian Cancer and Renal Cell Carcinoma (RCC)
Key Asset Highlights:
（1）This ADC platform adopts a clinically validated TOPO1 inhibitor payload and mature linker design, delivering a highly reliable and translatable therapeutic modality for CDH6-positive malignancies.
（2）Specifically targets CDH6, a tumor-specific cell adhesion molecule selectively overexpressed in ovarian cancer and renal cell carcinoma, enabling precise tumor localization and effective reduction of off-tumor cytotoxicity.
（3）Upon antigen-specific internalization, the conjugated TOPO1 inhibitor payload is efficiently released inside tumor cells, inducing severe DNA damage and robust cytotoxic anti-tumor activity.
（4）Demonstrates potent and durable anti-tumor efficacy in preclinical models of ovarian cancer and RCC, showing distinct differentiation and improved therapeutic window compared with existing targeted therapeutics.
（5）Possesses favorable stability, controllable drug-to-antibody ratio and excellent safety profiles, supporting continuous clinical evaluation and long-term therapeutic application for refractory solid tumors.
（6）Backed by a comprehensive global intellectual property portfolio, securing exclusive and stable worldwide development and commercialization rights for CDH6-positive solid tumor indications.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.